Mumbai, March 6 -- The approved drug is a generic version of Sprycel Tablets.

Dasatinib is used to treat Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in newly diagnosed adults, as well as in adults with resistance or intolerance to prior therapies, including imatinib. Dasatinib is also indicated for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in adults with resistance or intolerance to prior therapy.

The Dasatinib tablets will be manufactured at Zydus Lifesciences' facility in Ahmedabad.

According to IQVIA MAT January 2025 data, Dasatinib tablets generated annual sales of $1807.7 million in the United States.

With this approval, Zydus Lifesciences now holds 415 USFDA approvals, havi...